Takeda's tetravalent dengue vaccine meets in Phase III

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) said TAK-003 met the primary endpoint in Part 1 of the Phase III TIDES (DEN-301) trial to prevent dengue fever caused by any of the four serotypes of the virus. TAK-003 is a tetravalent dengue vaccine based on a live-attenuated dengue serotype 2 common backbone with chimeric viruses for serotypes 1, 3 and 4.

TIDES' primary endpoint evaluated the vaccine efficacy of two doses of TAK-003 (formerly DENVax) compared with placebo in preventing virologically confirmed dengue fever of any severity induced by any dengue serotype occurring from 1-12 months after the second dose in both dengue exposed and naïve subjects. TAK-003 was well tolerated with no significant safety concerns identified...